---
title: "H.C. Wainwright Remains a Buy on Bausch + Lomb Corporation (BLCO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285058751.md"
description: "H.C. Wainwright analyst Yi Chen has reiterated a Buy rating on Bausch + Lomb Corporation (BLCO) with a price target of $20.00. Chen, who focuses on the Healthcare sector, has an average return of 0.2% and a 40.89% success rate on his stock recommendations. Additionally, Citi's Joanne Wuensch also issued a Buy rating for Bausch + Lomb, while Stifel Nicolaus maintained a Hold rating on the same day."
datetime: "2026-05-04T10:36:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285058751.md)
  - [en](https://longbridge.com/en/news/285058751.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285058751.md)
---

# H.C. Wainwright Remains a Buy on Bausch + Lomb Corporation (BLCO)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation today and set a price target of $20.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Chen covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Opko Health, and CareDx. According to TipRanks, Chen has an average return of 0.2% and a 40.89% success rate on recommended stocks.

In addition to H.C. Wainwright, Bausch + Lomb Corporation also received a Buy from Citi’s Joanne Wuensch in a report issued on April 30. However, on the same day, Stifel Nicolaus maintained a Hold rating on Bausch + Lomb Corporation (NYSE: BLCO).

### Related Stocks

- [BLCO.US](https://longbridge.com/en/quote/BLCO.US.md)
- [OCUL.US](https://longbridge.com/en/quote/OCUL.US.md)
- [OPK.US](https://longbridge.com/en/quote/OPK.US.md)
- [CDNA.US](https://longbridge.com/en/quote/CDNA.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Bausch + Lomb Announces Second R&D “Teach-in” Webinar | BLCO Stock News](https://longbridge.com/en/news/285364834.md)
- [Short Interest in Bausch + Lomb Corporation (NYSE:BLCO) Increases By 50.7%](https://longbridge.com/en/news/280886928.md)
- [Bausch + Lomb (BLCO) Q1 Earnings Report Preview: What To Look For](https://longbridge.com/en/news/284302848.md)
- [Seres Therapeutics (MCRB) Gets a Buy from Canaccord Genuity](https://longbridge.com/en/news/285368363.md)
- [Wells Fargo Sticks to Their Buy Rating for Alumis Inc. (ALMS)](https://longbridge.com/en/news/285061728.md)